Updated Austrian treatment algorithm in HER2+ metastatic breast cancer

Wien Klin Wochenschr. 2022 Jan;134(1-2):63-72. doi: 10.1007/s00508-021-01987-9. Epub 2022 Jan 28.


A group of Austrian breast cancer specialists met in December 2020 to establish a comprehensive clinical benefit-risk profile of available HER2-targeted therapies based on recent data and to develop an updated treatment algorithm by consensus over several months in 2021. A total of four scenarios were developed in which treatment strategies appropriate for specific patient profiles were evaluated. Consensus was established by detailed discussions of each scenario and by reaching full consensus.

Keywords: Antibody-conjugate; HER2; Pertuzumab; Trastuzumab; Tyrosin-kinase inhibitor.

MeSH terms

  • Algorithms
  • Antibodies, Monoclonal, Humanized / therapeutic use
  • Antineoplastic Combined Chemotherapy Protocols
  • Austria
  • Breast Neoplasms* / drug therapy
  • Female
  • Humans
  • Receptor, ErbB-2 / genetics
  • Receptor, ErbB-2 / therapeutic use
  • Trastuzumab / therapeutic use


  • Antibodies, Monoclonal, Humanized
  • Receptor, ErbB-2
  • Trastuzumab